Pharsight

Micardis patents expiration

MICARDIS's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5591762 BOEHRINGER INGELHEIM Benzimidazoles useful as angiotensin-11 antagonists
Jan, 2014

(10 years ago)

US6358986 BOEHRINGER INGELHEIM Polymorphs of telmisartan
Jan, 2020

(4 years ago)

US7998953 BOEHRINGER INGELHEIM Use of inhibitors of the renin-angiotensin system
Jun, 2020

(4 years ago)

US8003679 BOEHRINGER INGELHEIM Use of inhibitors of the renin-angiotensin system
Oct, 2022

(1 year, 8 months ago)

Micardis is owned by Boehringer Ingelheim.

Micardis contains Telmisartan.

Micardis has a total of 4 drug patents out of which 4 drug patents have expired.

Expired drug patents of Micardis are:

  • US5591762
  • US6358986
  • US7998953
  • US8003679

Micardis was authorised for market use on 04 April, 2000.

Micardis is available in tablet;oral dosage forms.

Micardis can be used as treatment or prevention of stroke, treatment of hypertension, reduction of cardiac tissue damage associated with myocardial infarction.

The generics of Micardis are possible to be released after 06 October, 2022.

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-612) Oct 16, 2012

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using TELMISARTAN ingredient

Market Authorisation Date: 04 April, 2000

Treatment: Treatment of hypertension; Reduction of cardiac tissue damage associated with myocardial infarction; Treatment or prevention of stroke

Dosage: TABLET;ORAL

How can I launch a generic of MICARDIS before it's drug patent expiration?
More Information on Dosage

MICARDIS family patents

Family Patents